TMEM106B coding variant is protective and deletion detrimental in a mouse model of tauopathy

TMEM106B is a risk modifier for a growing list of age-associated dementias including Alzheimer’s and frontotemporal dementia, yet its function remains elusive. Two key questions that emerge from past work are whether the conservative T185S coding variant found in the minor haplotype contributes to protection, and whether the presence of TMEM106B is helpful or harmful in the context of disease. Here we address both issues while extending the testbed for study of TMEM106B from models of TDP to tauopathy. We show that TMEM106B deletion accelerates cognitive decline, hindlimb paralysis, neuropathology, and neurodegeneration. TMEM106B deletion also increases transcriptional overlap with human AD, making it a better model of disease than tau alone. In contrast, the coding variant protects against tau-associated cognitive decline, neurodegeneration, and paralysis without affecting tau pathology. Our findings show that the coding variant contributes to neuroprotection and suggest that TMEM106B is a critical safeguard against tau aggregation.

[1]  M. Colonna The biology of TREM receptors , 2023, Nature Reviews Immunology.

[2]  J. Richter,et al.  Lack of a protective effect of the Tmem106b “protective SNP” in the Grn knockout mouse model for frontotemporal lobar degeneration , 2023, Acta Neuropathologica Communications.

[3]  Jolien Perneel,et al.  Identification of TMEM106B amyloid fibrils provides an updated view of TMEM106B biology in health and disease , 2022, Acta Neuropathologica.

[4]  C. Pang,et al.  Growth hormone-releasing hormone receptor signaling in experimental ocular inflammation and neuroprotection , 2022, Neural regeneration research.

[5]  D. Eisenberg,et al.  Amyloid fibrils in FTLD-TDP are composed of TMEM106B and not TDP-43 , 2022, Nature.

[6]  L. Petrucelli,et al.  Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases , 2022, Cell.

[7]  A. Murzin,et al.  Age-Dependent Formation of TMEM106B Amyloid Filaments in Human Brain , 2021, bioRxiv.

[8]  Tuancheng Feng,et al.  Physiological and pathological functions of TMEM106B: a gene associated with brain aging and multiple brain disorders , 2021, Acta Neuropathologica.

[9]  W. Wurst,et al.  Loss of TMEM106B potentiates lysosomal and FTLD‐like pathology in progranulin‐deficient mice , 2020, EMBO reports.

[10]  Haiyuan Yu,et al.  Loss of TMEM106B and PGRN leads to severe lysosomal abnormalities and neurodegeneration in mice , 2020, EMBO reports.

[11]  D. Dickson,et al.  Loss of Tmem106b exacerbates FTLD pathologies and causes motor deficits in progranulin‐deficient mice , 2020, EMBO reports.

[12]  James A. Eddy,et al.  Meta-Analysis of the Alzheimer’s Disease Human Brain Transcriptome and Functional Dissection in Mouse Models , 2020, Cell reports.

[13]  Y. Asmann,et al.  Loss of TMEM106B leads to myelination deficits: implications for frontotemporal dementia treatment strategies. , 2020, Brain : a journal of neurology.

[14]  R. D'Hooge,et al.  The FTLD Risk Factor TMEM106B Regulates the Transport of Lysosomes at the Axon Initial Segment of Motoneurons. , 2020, Cell reports.

[15]  Giovanni Parmigiani,et al.  ComBat-seq: batch effect adjustment for RNA-seq count data , 2020, bioRxiv.

[16]  J. Morris,et al.  The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion , 2019, Acta Neuropathologica.

[17]  Hong Lu,et al.  Wnt-3a alleviates neuroinflammation after ischemic stroke by modulating the responses of microglia/macrophages and astrocytes. , 2019, International immunopharmacology.

[18]  R. Schuepbach,et al.  Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases , 2019, Thrombosis Journal.

[19]  I. Marriott,et al.  The Interleukin-10 Family of Cytokines and Their Role in the CNS , 2018, Front. Cell. Neurosci..

[20]  Benjamin A. Logsdon,et al.  The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease , 2018, Scientific Data.

[21]  A. Yang,et al.  Genome‐wide analysis reveals TNFAIP8L2 as an immune checkpoint regulator of inflammation and metabolism , 2018, Molecular immunology.

[22]  L. Petrucelli,et al.  Loss of Tmem106b is unable to ameliorate frontotemporal dementia-like phenotypes in an AAV mouse model of C9ORF72-repeat induced toxicity , 2018, Acta neuropathologica communications.

[23]  Charles C. White,et al.  A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer’s disease , 2018, Nature Neuroscience.

[24]  Hans-Ulrich Klein,et al.  A multi-omic atlas of the human frontal cortex for aging and Alzheimer’s disease research , 2018, Scientific Data.

[25]  Christopher D. Brown,et al.  A dementia-associated risk variant near TMEM106B alters chromatin architecture and gene expression , 2017, bioRxiv.

[26]  Jacqueline A. Brinkman,et al.  Neuropeptide FF increases M2 activation and self-renewal of adipose tissue macrophages. , 2017, The Journal of clinical investigation.

[27]  S. Strittmatter,et al.  Loss of TMEM106B Ameliorates Lysosomal and Frontotemporal Dementia-Related Phenotypes in Progranulin-Deficient Mice , 2017, Neuron.

[28]  M. Shamloo,et al.  Role of Endoplasmic Reticulum Stress in Learning and Memory Impairment and Alzheimer's Disease-Like Neuropathology in the PS19 and APPSwe Mouse Models of Tauopathy and Amyloidosis , 2017, eNeuro.

[29]  Shu-Hsia Chen,et al.  LILRB receptor-mediated regulation of myeloid cell maturation and function , 2017, Cancer Immunology, Immunotherapy.

[30]  I. Amit,et al.  A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease , 2017, Cell.

[31]  H. Rhinn,et al.  Differential Aging Analysis in Human Cerebral Cortex Identifies Variants in TMEM106B and GRN that Regulate Aging Phenotypes. , 2017, Cell systems.

[32]  Charles C. White,et al.  Identification of genes associated with dissociation of cognitive performance and neuropathological burden: Multistep analysis of genetic, epigenetic, and transcriptional data , 2017, PLoS medicine.

[33]  James A. Eddy,et al.  Human whole genome genotype and transcriptome data for Alzheimer’s and other neurodegenerative diseases , 2016, Scientific Data.

[34]  Alexandra M. Nicholson,et al.  What we know about TMEM106B in neurodegeneration , 2016, Acta Neuropathologica.

[35]  Kang Chen,et al.  Wnt3a suppresses Pseudomonas aeruginosa-induced inflammation and promotes bacterial killing in macrophages , 2016, Molecular medicine reports.

[36]  B. Kaang,et al.  TMEM106B, a frontotemporal lobar dementia (FTLD) modifier, associates with FTD-3-linked CHMP2B, a complex of ESCRT-III , 2015, Molecular Brain.

[37]  A. Bartke,et al.  Growth hormone modulates hypothalamic inflammation in long‐lived pituitary dwarf mice , 2015, Aging cell.

[38]  H. Randeva,et al.  Orexin receptors exert a neuroprotective effect in Alzheimer’s disease (AD) via heterodimerization with GPR103 , 2015, Scientific Reports.

[39]  N. Krogan,et al.  Critical Role of Acetylation in Tau-Mediated Neurodegeneration and Cognitive Deficits , 2015, Nature Medicine.

[40]  J. Cirrito,et al.  Genetic Modulation of Soluble Aβ Rescues Cognitive and Synaptic Impairment in a Mouse Model of Alzheimer's Disease , 2014, The Journal of Neuroscience.

[41]  L. Fitzpatrick,et al.  Inflammation-induced functional connectivity of melanin-concentrating hormone and IL-10 , 2014, Peptides.

[42]  D. Holtzman,et al.  Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo , 2013, Neuron.

[43]  B. Boeve,et al.  TMEM106B p.T185S regulates TMEM106B protein levels: implications for frontotemporal dementia , 2013, Journal of neurochemistry.

[44]  J. Schneider,et al.  Overview and findings from the religious orders study. , 2012, Current Alzheimer research.

[45]  J. Trojanowski,et al.  The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice , 2012, The Journal of Neuroscience.

[46]  J. Trojanowski,et al.  P301S Mutant Human Tau Transgenic Mice Manifest Early Symptoms of Human Tauopathies with Dementia and Altered Sensorimotor Gating , 2011, PloS one.

[47]  K. Sleegers,et al.  TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort , 2011, Brain : a journal of neurology.

[48]  M. J. Fresnadillo Martínez,et al.  Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions , 2010, Nature Genetics.

[49]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[50]  B. Williams,et al.  Mapping and quantifying mammalian transcriptomes by RNA-Seq , 2008, Nature Methods.

[51]  Bin Zhang,et al.  Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model , 2007, Neuron.

[52]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[53]  M. Hofker Faculty Opinions recommendation of PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. , 2003 .

[54]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[55]  Reynaldo Sequerra,et al.  High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP , 2000, Nature Genetics.

[56]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[57]  M. Dąbrowski,et al.  Gng12 is a novel negative regulator of LPS-induced inflammation in the microglial cell line BV-2 , 2009, Inflammation Research.

[58]  G. Martin,et al.  Analysis of Fgf8 gene function in vertebrate development. , 1997, Cold Spring Harbor symposia on quantitative biology.

[59]  P. Demoly,et al.  [Transgenic mice]. , 1992, Annales de dermatologie et de venereologie.